🏠

🚀 Enveda Raises $311M: Biotech Breakthrough! ✨

September 23, 2026 | Author

Science

🎧 Audio Summaries
English flag
French flag
German flag
Japanese flag
Korean flag
Mandarin flag
Spanish flag

🧠Quick Intel


  • Enveda raised $311 million in Series E funding at a $2 billion valuation, doubling its previous valuation from 12 months prior.
  • Catalio Capital Management led the $311 million Series E round, with participation from Iconiq.
  • Viswa Colluru founded Enveda in 2019, leveraging AI to accelerate drug discovery from natural sources.
  • Enveda is currently testing multiple drugs in human clinical trials, including treatments for severe skin conditions and weight loss maintenance after GLP-1 cessation.
  • The company’s approach focuses on harnessing medicines from plants and microbes, rather than traditional lab synthesis.

    • 📝Summary


    Enveda, a biotechnology company utilizing artificial intelligence to identify novel drugs from natural sources, recently secured $311 million in Series E funding. Led by Catalio Capital Management, this investment values the company at $2 billion, doubling its valuation from a year prior. Founded in 2019 by Viswa Colluru, a former Recursion Pharmaceuticals employee, Enveda aims to accelerate drug discovery by leveraging AI and other techniques. The company is currently conducting human clinical trials for several drugs, including treatments for severe skin conditions and aids in post-GLP-1 weight management. This represents a significant step for AI-discovered drug candidates entering the medical landscape.

    💡Insights

    ▼


    ENVEDA’S GROUNDBREAKING FUNDING ROUND
    Enveda, a pioneering biotech firm leveraging artificial intelligence to uncover novel therapeutics from the natural world, has secured a significant $311 million in Series E funding. This substantial investment, led by Catalio Capital Management with key participation from Iconiq, has propelled Enveda’s valuation to a remarkable $2 billion – effectively doubling the company’s previous valuation achieved just twelve months prior. This funding round underscores the growing confidence in Enveda’s innovative approach to drug discovery, which centers on harnessing the potential of plants and microbes rather than traditional, lab-synthesized methods.

    THE VISION BEHIND ENVEDA: AI-POWERED NATURAL DISCOVERY
    Founded in 2019 by Viswa Colluru, a former employee of Recursion Pharmaceuticals, Enveda’s core concept revolves around accelerating drug discovery through the strategic combination of artificial intelligence and other advanced techniques. The company’s strategy recognizes that many potent medicines already exist within the vast biodiversity of the natural world – residing in plants and microbes – and that AI can dramatically expedite the process of identifying and validating these compounds. While AI’s impact on drug approvals is still developing, Enveda is at the forefront of this emerging trend, actively progressing AI-discovered drug candidates through crucial stages of human clinical trials.

    CURRENT DRUG DEVELOPMENT & CLINICAL TRIALS
    Currently, Enveda is diligently testing several promising drug candidates within patient populations. Notably, the company is conducting trials for a treatment targeting severe skin conditions, representing a significant unmet medical need. Furthermore, Enveda is exploring a drug designed to assist with weight maintenance following cessation of GLP-1 medications, addressing a growing area of interest in metabolic health management. These clinical trials represent a vital step in translating Enveda’s AI-driven discoveries into tangible therapies for patients.

    Related Articles